Pulse Biosciences [PLSE] vs Becton, Dickinson [BDX] Detailed Stock Comparison
Pulse Biosciences
NASDAQ
Loading...
Becton, Dickinson
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Pulse Biosciences wins in 5 metrics, Becton, Dickinson wins in 10 metrics, with 0 ties. Becton, Dickinson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pulse Biosciences | Becton, Dickinson | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -20.97 | 35.46 | Pulse Biosciences |
| Price-to-Book Ratio | 12.42 | 2.18 | Becton, Dickinson |
| Debt-to-Equity Ratio | 7.89 | 75.93 | Pulse Biosciences |
| PEG Ratio | -0.52 | 1.86 | Pulse Biosciences |
| EV/EBITDA | -16.87 | 12.52 | Pulse Biosciences |
| Profit Margin (TTM) | 0.00% | 7.41% | Becton, Dickinson |
| Operating Margin (TTM) | 0.00% | 17.81% | Becton, Dickinson |
| EBITDA Margin (TTM) | N/A | 17.81% | N/A |
| Return on Equity | -103.50% | 6.18% | Becton, Dickinson |
| Return on Assets (TTM) | -56.19% | 3.96% | Becton, Dickinson |
| Free Cash Flow (TTM) | $-36.47M | $3.07B | Becton, Dickinson |
| Dividend Yield | N/A | 1.80% | N/A |
| 1-Year Return | 13.88% | -18.82% | Pulse Biosciences |
| Price-to-Sales Ratio (TTM) | N/A | 2.59 | N/A |
| Enterprise Value | $1.20B | $74.08B | Becton, Dickinson |
| EV/Revenue Ratio | N/A | 3.46 | N/A |
| Gross Profit Margin (TTM) | N/A | 47.81% | N/A |
| Revenue per Share (TTM) | $0 | $74 | Becton, Dickinson |
| Earnings per Share (Diluted) | $-1.08 | $5.46 | Becton, Dickinson |
| Beta (Stock Volatility) | 1.79 | 0.28 | Becton, Dickinson |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Pulse Biosciences vs Becton, Dickinson Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pulse Biosciences | 0.83% | 9.27% | 29.32% | 23.02% | 28.30% | 9.33% |
| Becton, Dickinson | -0.84% | 4.34% | 0.21% | 11.01% | -6.38% | -15.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pulse Biosciences | 13.88% | 760.62% | 32.22% | 370.94% | 370.94% | 370.94% |
| Becton, Dickinson | -18.82% | -14.56% | -16.96% | 41.00% | 158.50% | 282.68% |
News Based Sentiment: Pulse Biosciences vs Becton, Dickinson
Pulse Biosciences
News based Sentiment: MIXED
The month presented a mixed bag for Pulse Biosciences, with positive developments like the equity incentive plan approval and CEO confirmation countered by concerns about financial performance and operational costs. The analyst ratings reflect this duality, making it a moderately significant month for investors.
Becton, Dickinson
News based Sentiment: POSITIVE
BDX delivered a strong October, exceeding earnings expectations and raising guidance, fueled by strategic investments in pharmacy automation and continued institutional support. While insider selling is a minor concern, the overall narrative points to positive momentum and growth potential, making it a significant month for investors.
Performance & Financial Health Analysis: Pulse Biosciences vs Becton, Dickinson
| Metric | PLSE | BDX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.30B | $55.67B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 191,492 | 1,421,540 |
| 90 Day Avg. Volume | 217,904 | 1,589,433 |
| Last Close | $19.45 | $191.99 |
| 52 Week Range | $13.77 - $25.00 | $163.33 - $251.99 |
| % from 52W High | -22.20% | -23.81% |
| All-Time High | $45.82 (Feb 08, 2021) | $287.32 (Jul 24, 2023) |
| % from All-Time High | -57.55% | -33.18% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.10% |
| Quarterly Earnings Growth | N/A | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.07% |
| Operating Margin (TTM) | 0.00% | 0.18% |
| Return on Equity (TTM) | -1.04% | 0.06% |
| Debt to Equity (MRQ) | 7.89 | 75.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.55 | $88.87 |
| Cash per Share (MRQ) | $1.58 | $2.64 |
| Operating Cash Flow (TTM) | $-44,496,000 | $3.25B |
| Levered Free Cash Flow (TTM) | $-21,688,876 | $3.37B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.80% |
| Last 12-Month Dividend | N/A | $3.03 |
Valuation & Enterprise Metrics Analysis: Pulse Biosciences vs Becton, Dickinson
| Metric | PLSE | BDX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -20.97 | 35.46 |
| Forward P/E | -21.43 | 12.31 |
| PEG Ratio | -0.52 | 1.86 |
| Price to Sales (TTM) | N/A | 2.59 |
| Price to Book (MRQ) | 12.42 | 2.18 |
| Market Capitalization | ||
| Market Capitalization | $1.30B | $55.67B |
| Enterprise Value | $1.20B | $74.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 3.46 |
| Enterprise to EBITDA | -16.87 | 12.52 |
| Risk & Other Metrics | ||
| Beta | 1.79 | 0.28 |
| Book Value per Share (MRQ) | $1.55 | $88.87 |
Financial Statements Comparison: Pulse Biosciences vs Becton, Dickinson
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PLSE | BDX |
|---|---|---|
| Revenue/Sales | $0 | $5.51B |
| Cost of Goods Sold | N/A | $2.88B |
| Gross Profit | N/A | $2.63B |
| Research & Development | $10.31M | $297.00M |
| Operating Income (EBIT) | $-18.04M | $979.00M |
| EBITDA | $-17.76M | $1.57B |
| Pre-Tax Income | $-16.80M | $703.00M |
| Income Tax | $0 | $129.00M |
| Net Income (Profit) | $-16.80M | $574.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PLSE | BDX |
|---|---|---|
| Cash & Equivalents | $119.28M | $667.00M |
| Total Current Assets | $120.91M | $8.67B |
| Total Current Liabilities | $7.76M | $7.69B |
| Long-Term Debt | $7.17M | $17.67B |
| Total Shareholders Equity | $118.45M | $25.24B |
| Retained Earnings | $-407.30M | $16.15B |
| Property, Plant & Equipment | $8.25M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PLSE | BDX |
|---|---|---|
| Operating Cash Flow | $-10.20M | $941.00M |
| Capital Expenditures | $-45,000 | N/A |
| Free Cash Flow | $-13.57M | $35.00M |
| Debt Repayment | N/A | $-1.00M |
| Common Stock Repurchase | N/A | $0 |
Short Interest & Institutional Ownership Analysis
| Metric | PLSE | BDX |
|---|---|---|
| Shares Short | 2.54M | 4.28M |
| Short Ratio | 14.11 | 2.41 |
| Short % of Float | 0.14% | 0.02% |
| Average Daily Volume (10 Day) | 191,492 | 1,421,540 |
| Average Daily Volume (90 Day) | 217,904 | 1,589,433 |
| Shares Outstanding | 65.93M | 289.10M |
| Float Shares | 17.25M | 286.00M |
| % Held by Insiders | 0.74% | 0.01% |
| % Held by Institutions | 0.09% | 0.92% |
Dividend Analysis & Yield Comparison: Pulse Biosciences vs Becton, Dickinson
| Metric | PLSE | BDX |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.03 |
| Last 12-Month Dividend Yield | N/A | 1.80% |
| 3-Year Avg Annual Dividend | N/A | $3.16 |
| 3-Year Avg Dividend Yield | N/A | 0.40% |
| 3-Year Total Dividends | N/A | $9.48 |
| Ex-Dividend Date | N/A | Mar 10, 2025 |